COVID-19 treatments and prevention: Interested in receiving COVID-19 treatment?

If you are positive for COVID-19 and want to submit a request for a COVID-19 treatment, including antiviral medications, please complete the online survey form.


Antiviral therapies

Most people who become ill with COVID-19 will be able to recover at home. Some of the same things you do to treat other respiratory infections — getting plenty of rest, hydration, nutrition and taking pain medications to relieve fever and aches and pains — also help with COVID-19.

The U.S. Food and Drug Administration (FDA) authorized the emergency use of antiviral therapies with priority to people at the highest risk for hospitalization or death.


Learn about COVID-19 therapies and medication

Here are common questions about COVID-19 therapies and medication, in addition to who is eligible to receive treatment.

Antiviral treatments are oral (pills) and IV medications that stop the coronavirus from replicating. Oral and IV antiviral medications are investigational medicine for patients who have tested positive for COVID-19 and meet certain criteria.

Names for oral antiviral drugs include remdesivir (Veklury), molnupiravir (Lagevrio) and nirmatrelvir/ritonavir (Paxlovid).

When you have a virus, your immune system creates antibodies to help fight off the virus. Monoclonal antibody drug therapy contains man-made antibodies that are similar (clones) to the antibodies your immune system makes.

Antibody therapy for people that have tested positive for COVID-19 is an investigational medicine for people that meet certain criteria. The drug is given through a vein (intravenous or IV) in one dose for 20 to 30 minutes. The total appointment takes about two to three hours.

Some names of antibody therapy drugs administered to people with COVID-19 infection include bamlanivimab plus etesevimab or casirivimab plus imdevimab or sotrovimab.

New viral strains may become resistant to monoclonal antibodies, and monoclonal antibodies might not always be available.

Patients who test positive for COVID-19, have mild to moderate symptoms and are not hospitalized or requiring new oxygen therapy or an increase in oxygen therapy due to COVID-19 might be eligible for this treatment option. Patients also must have risk factors for developing severe COVID-19 that results in hospitalization or death.

  • Cancer

  • Chronic kidney disease

  • Chronic liver disease

  • Chronic lung disease (asthma, bronchiectasis, COPD, interstitial lung disease, pulmonary fibrosis, cystic fibrosis, pulmonary embolism, pulmonary hypertension)

  • Dementia or other neurological condition

  • Diabetes (type 1 or 2)

  • Down syndrome

  • Heart condition (heart failure, coronary artery disease, cardiomyopathy, high blood pressure (hypertension)

  • HIV infection

  • Immunocompromised state (weakened immune system) from an inflammatory or autoimmune disease or immunosuppressive medicine

  • Mental health condition (mood disorder, depression, schizophrenia)

  • Pregnancy

  • Sickle cell disease or thalassemia

  • Smoking, current or former

  • Solid organ or blood stem cell transplant

  • Stroke or cerebrovascular disease, which affects blood flow to the brain

  • Substance use disorder (such as alcohol, opioid or cocaine use disorder)

  • Tuberculosis

  • Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)

  • Medical-related technological dependence (for example, tracheostomy, gastrostomy or positive pressure ventilation, not related to COVID-19)

Pre-exposure prophylaxis monoclonal antibody drug therapy is a preventative treatment given to people who are not currently infected with COVID-19 and who have not recently been exposed to someone infected with COVID-19.

The investigational drug is given to people that meet certain criteria through intramuscular injections. Preventative monoclonal antibody treatment is for vaccinated patients with weakened immune systems or those unable to get a COVID-19 vaccine for medical reasons who do not have COVID-19 infection.

Names for prophylaxis monoclonal antibody therapy drugs include tixagevimab/cilgavimab (Evusheld).

Treatments and vaccines can help offer protection from COVID-19, but they are different. Antibody therapy and antiviral medications can help a patient who is sick with COVID-19 fight off the infection. Pre-exposure prophylaxis (prevention) is not a substitute for vaccination for people that COVID-19 vaccination is recommended. A COVID-19 vaccine offers protection from future viruses, but cannot treat a patient who is already sick.

The U.S. Food and Drug Administration (FDA) authorized the emergency use of these drug therapies only during the COVID-19 pandemic. This authorization is different than FDA approval. These drugs are investigational and still being studied, so there is limited information known at this time about their safety and effectiveness.

In times of high demand and/or an extremely limited supply of COVID-19 treatments, including monoclonal antibody infusions (i.e., sotrovimab) and antiviral therapies (i.e, Veklury, Paxlovid, molnupiravir), priority will be given to individuals at the very highest risk of serious illness or death.

If you are positive for COVID-19 infection and want to submit a request for UW Health supply, please click below and complete our online survey form.

If you need assistance completing the online survey form, you can call our hotline at (608) 720-3319. Please be aware in times of high call volumes there may be delays in reaching someone by phone. The fastest way to be considered is by submitting the online form.

Completing the survey or calling the hotline does not guarantee treatment will be provided. If you meet the criteria for treatment options and treatment is available, you will be contacted by UW Health directly. Please do not call multiple times. If you do not receive a call back, this means that we unfortunately are unable to provide you therapy.

Complete our request form

Patients interested in preventative monoclonal antibody treatment should contact the provider managing their condition or current prescription that weakens their immune system. There is also an extremely limited supply of Evusheld (tixagevimab/cilgavimab), so priority is being given to individuals at the very highest risk of serious illness or death. The Evusheld preventative treatment can only be obtained through a physician prescription and is not a substitute for vaccination.


Medication information